NO324037B1 - Pulver for anvendelse i en torrpulverinhalator og fremgangsmate for fremstilling av pulveret - Google Patents
Pulver for anvendelse i en torrpulverinhalator og fremgangsmate for fremstilling av pulveret Download PDFInfo
- Publication number
- NO324037B1 NO324037B1 NO19973502A NO973502A NO324037B1 NO 324037 B1 NO324037 B1 NO 324037B1 NO 19973502 A NO19973502 A NO 19973502A NO 973502 A NO973502 A NO 973502A NO 324037 B1 NO324037 B1 NO 324037B1
- Authority
- NO
- Norway
- Prior art keywords
- particles
- powder
- additive material
- active
- additive
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 133
- 229940112141 dry powder inhaler Drugs 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000002245 particle Substances 0.000 claims abstract description 458
- 239000000654 additive Substances 0.000 claims abstract description 158
- 230000000996 additive effect Effects 0.000 claims abstract description 157
- 239000000463 material Substances 0.000 claims abstract description 126
- 239000011149 active material Substances 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 68
- 239000008101 lactose Substances 0.000 claims description 66
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 43
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 38
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 24
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 24
- 238000000227 grinding Methods 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000004033 plastic Substances 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 229960002052 salbutamol Drugs 0.000 claims description 8
- 239000008347 soybean phospholipid Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 7
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 239000005639 Lauric acid Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000021357 Behenic acid Nutrition 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229940116226 behenic acid Drugs 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940087559 grape seed Drugs 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 229940093740 amino acid and derivative Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 65
- 229960001375 lactose Drugs 0.000 description 65
- 229960003136 leucine Drugs 0.000 description 46
- 210000004072 lung Anatomy 0.000 description 29
- 239000000523 sample Substances 0.000 description 22
- 210000003437 trachea Anatomy 0.000 description 18
- 235000013339 cereals Nutrition 0.000 description 15
- 239000002775 capsule Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000008021 deposition Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 229910052573 porcelain Inorganic materials 0.000 description 10
- 239000004395 L-leucine Substances 0.000 description 9
- 235000019454 L-leucine Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000000181 anti-adherent effect Effects 0.000 description 7
- 239000003911 antiadherent Substances 0.000 description 7
- 235000019592 roughness Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000004570 mortar (masonry) Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 229940127557 pharmaceutical product Drugs 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 5
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- 229960004436 budesonide Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000005204 segregation Methods 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003831 antifriction material Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101100154696 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) tsi1 gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- OEXHQOGQTVQTAT-BZQJJPTISA-N [(1s,5r)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C(C)C)C2OC(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-BZQJJPTISA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- VXAUWWUXCIMFIM-UHFFFAOYSA-M aluminum;oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Al+3] VXAUWWUXCIMFIM-UHFFFAOYSA-M 0.000 description 1
- 239000000596 artificial lung surfactant Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- 235000019587 texture Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501841.2A GB9501841D0 (en) | 1995-01-31 | 1995-01-31 | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GBGB9521937.4A GB9521937D0 (en) | 1995-01-31 | 1995-10-26 | Improvementsin and relating to carrier particles for use in dry powder inhailers |
| PCT/GB1996/000215 WO1996023485A1 (en) | 1995-01-31 | 1996-01-31 | Carrier particles for use in dry powder inhalers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973502D0 NO973502D0 (no) | 1997-07-30 |
| NO973502L NO973502L (no) | 1997-09-30 |
| NO324037B1 true NO324037B1 (no) | 2007-07-30 |
Family
ID=10768844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973502A NO324037B1 (no) | 1995-01-31 | 1997-07-30 | Pulver for anvendelse i en torrpulverinhalator og fremgangsmate for fremstilling av pulveret |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US6153224A (es) |
| EP (6) | EP2213279A3 (es) |
| JP (1) | JP4042867B2 (es) |
| KR (1) | KR100500694B1 (es) |
| CN (1) | CN1303974C (es) |
| AT (3) | ATE256450T1 (es) |
| AU (1) | AU699131B2 (es) |
| BG (1) | BG101858A (es) |
| BR (3) | BRPI9612950B8 (es) |
| CA (1) | CA2211874C (es) |
| CZ (1) | CZ294259B6 (es) |
| DE (2) | DE69631119T2 (es) |
| DK (3) | DK1666023T3 (es) |
| EA (1) | EA000352B1 (es) |
| EE (1) | EE9700176A (es) |
| ES (3) | ES2278828T3 (es) |
| FI (1) | FI119676B (es) |
| GB (2) | GB9501841D0 (es) |
| GE (1) | GEP19991687B (es) |
| HK (1) | HK1084897A1 (es) |
| HU (1) | HU229965B1 (es) |
| IS (1) | IS4531A (es) |
| MX (1) | MX9705847A (es) |
| NO (1) | NO324037B1 (es) |
| NZ (1) | NZ300654A (es) |
| PL (1) | PL186757B1 (es) |
| PT (3) | PT806938E (es) |
| SI (2) | SI1666023T1 (es) |
| SK (1) | SK282630B6 (es) |
| TR (1) | TR199700722T1 (es) |
| UA (1) | UA61051C2 (es) |
| WO (1) | WO1996023485A1 (es) |
| ZA (1) | ZA96721B (es) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| AUPN661995A0 (en) | 1995-11-16 | 1995-12-07 | Memtec America Corporation | Electrochemical cell 2 |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| GB9806477D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved crystals |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| CZ303154B6 (cs) * | 1998-11-13 | 2012-05-09 | Jagotec Ag | Suchá prášková formulace k inhalaci obsahující stearát horecnatý |
| GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| AU776782C (en) * | 1999-03-03 | 2005-04-07 | Eli Lilly And Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| RU2001126723A (ru) * | 1999-03-03 | 2003-09-27 | Эли Лилли энд Компани (US) | Эхинокандин/углеводные комплексы |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| ITMI991582A1 (it) | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
| US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US7252840B1 (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| AU7685200A (en) * | 1999-10-12 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Powdery inhalational preparations and process for producing the same |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| CA2401288A1 (en) * | 2000-02-28 | 2001-09-07 | Vectura Limited | Improvements in or relating to the delivery of oral drugs |
| JP2004515260A (ja) * | 2000-04-11 | 2004-05-27 | デュラ・ファーマシューティカルズ・インコーポレイテッド | 物理的に安定化された乾燥粉末製剤 |
| GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| DE60128902T2 (de) * | 2000-04-17 | 2008-02-14 | Vectura Ltd., Chippenham | Formulierungen zur verwendung in inhalationsvorrichtungen |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| AU6926101A (en) * | 2000-06-27 | 2002-01-08 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| EP1913939B1 (en) | 2000-06-27 | 2017-05-31 | Vectura Limited | Formulations for use in inhaler devices |
| JP2004509920A (ja) * | 2000-09-29 | 2004-04-02 | ボード オブ トラスティーズ オペレーティング ミシガン ステート ユニヴァーシティ | カテコールアミン医薬組成物および方法 |
| WO2002043693A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
| WO2002043702A2 (en) † | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
| ES2689704T3 (es) | 2000-11-30 | 2018-11-15 | Vectura Limited | Partículas para usar en una composición farmacéutica |
| ATE517607T1 (de) | 2000-11-30 | 2011-08-15 | Vectura Ltd | Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung |
| GB0030074D0 (en) * | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
| WO2002056948A1 (en) | 2001-01-17 | 2002-07-25 | Vectura Limited | An inhaler device |
| EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| US6681768B2 (en) | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
| AU2002333644A1 (en) * | 2001-09-17 | 2003-04-01 | Glaxo Group Limited | Dry powder medicament formulations |
| ES2415654T3 (es) * | 2001-11-20 | 2013-07-26 | Civitas Therapeutics, Inc. | Composiciones particuladas mejoradas para suministro pulmonar |
| WO2003043603A1 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
| US7641823B2 (en) * | 2001-12-07 | 2010-01-05 | Map Pharmaceuticals, Inc. | Synthesis of small particles |
| EP1490031A1 (en) | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| AU2006220411B2 (en) * | 2002-03-20 | 2008-06-26 | Alkermes, Inc. | Inhalable Sustained Therapeutic Formulations |
| EP1487411B1 (en) * | 2002-03-20 | 2019-01-02 | Civitas Therapeutics, Inc. | Inhalable sustained therapeutic formulations |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| GB0210527D0 (en) * | 2002-05-08 | 2002-06-19 | Univ Bath | Process for the treatment of particles for use in pharmaceutical formulations |
| US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| US20050158248A1 (en) * | 2002-08-21 | 2005-07-21 | Xian-Ming Zeng | Method of preparing dry powder inhalation compositions |
| GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| KR101369631B1 (ko) * | 2002-08-21 | 2014-03-05 | 노턴 헬스케어 리미티드 | 흡입용 조성물 |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| ES2520841T3 (es) * | 2003-02-21 | 2014-11-11 | University Of Bath | Procedimiento para la producción de partículas |
| EP1617820B1 (en) | 2003-04-14 | 2018-03-21 | Vectura Limited | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| US20050026886A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
| WO2005025535A2 (en) * | 2003-09-15 | 2005-03-24 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| AU2005237523A1 (en) | 2004-04-23 | 2005-11-10 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| WO2006055950A1 (en) * | 2004-11-18 | 2006-05-26 | Nektar Therapeutics | Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| CN104177448A (zh) * | 2005-02-10 | 2014-12-03 | 葛兰素集团有限公司 | 使用预分选技术制备乳糖的方法以及由此形成的药物制剂 |
| KR101488403B1 (ko) | 2005-05-18 | 2015-02-04 | 엠펙스 파마슈티컬즈, 인코포레이티드 | 에어로졸화된 플루오로퀴놀론 및 이의 용도 |
| US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| EP1954246A4 (en) * | 2005-11-11 | 2012-01-18 | Biolab Sanus Farmaceutica Ltda | SOLID PHARMACEUTICAL COMPOSITION WITH AGGLOMERATE NANOTEILES AND MANUFACTURING METHOD THEREFOR |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| EP1973523A2 (en) * | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| GB0602897D0 (en) * | 2006-02-13 | 2006-03-22 | Jagotec Ag | Improvements In Or Relating To Dry Powder Inhaler Devices |
| CN101437562A (zh) * | 2006-03-03 | 2009-05-20 | Stc.Unm公司 | 具有气动力弹性分散机构的干粉吸入器 |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0622818D0 (en) * | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0625303D0 (en) * | 2006-12-19 | 2007-01-24 | Jagotec Ag | Improvements in and relating to metered dose inhalers |
| WO2008134817A1 (en) * | 2007-05-03 | 2008-11-13 | The University Of Sydney | Composite carriers for dry powder inhalation therapy |
| US20090048155A1 (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| CA2709772A1 (en) | 2007-12-21 | 2009-07-09 | Endacea, Inc. | A1 adenosine receptor antagonists |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| CA2723314C (en) | 2008-02-13 | 2017-01-10 | The Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2296628B1 (en) * | 2008-05-22 | 2014-05-14 | 3M Innovative Properties Company | Process for manufacturing flowable powder drug compositions |
| EP2309978B1 (en) * | 2008-06-26 | 2018-12-26 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
| US9861580B2 (en) * | 2008-07-02 | 2018-01-09 | 3M Innovative Properties Company | Method of making a dry powder pharmaceutical composition |
| CA2732585A1 (en) | 2008-07-30 | 2010-02-04 | Stc.Unm | Formulations containing large-size carrier particles for dry powder inhalation aerosols |
| HUE038428T2 (hu) | 2008-10-07 | 2018-10-29 | Horizon Orphan Llc | Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében |
| WO2010042549A1 (en) | 2008-10-07 | 2010-04-15 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| PT3578169T (pt) | 2009-02-26 | 2024-07-29 | Glaxo Group Ltd | Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol |
| CA2759041A1 (en) * | 2009-04-24 | 2010-10-28 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
| PT2473170T (pt) | 2009-09-04 | 2019-08-23 | Horizon Orphan Llc | Utilização de levofloxacina em aerossol para tratamento de fibrose cística |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| AU2010319328A1 (en) | 2009-11-12 | 2012-05-31 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| US9877967B2 (en) | 2010-01-26 | 2018-01-30 | Endacea, Inc. | Methods and pharmaceutical compositions for preventing and treating renal impairment |
| NO2560611T3 (es) | 2010-04-21 | 2018-06-02 | ||
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| WO2012073025A1 (en) | 2010-11-30 | 2012-06-07 | Vectura Limited | Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd |
| WO2012078804A1 (en) | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
| US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| ES2683254T3 (es) * | 2012-01-25 | 2018-09-25 | Chiesi Farmaceutici S.P.A. | Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación |
| US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
| US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
| MY171125A (en) | 2012-03-13 | 2019-09-26 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| CA3172586A1 (en) | 2013-07-31 | 2015-02-05 | Avalyn Pharma Inc. | Aerosol imatininb compounds and uses thereof |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| WO2015179369A1 (en) | 2014-05-20 | 2015-11-26 | Infinity Pharmaceuticals, Inc. | Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors |
| MY181647A (en) | 2014-09-09 | 2020-12-30 | Vectura Ltd | Formulation comprising glycopyrrolate, method and apparatus |
| EP3212212B1 (en) | 2014-10-31 | 2020-09-23 | Monash University | Powder formulation |
| JP6499288B2 (ja) | 2014-11-26 | 2019-04-10 | ヴェクトュラ・デリヴァリー・ディヴァイスィズ・リミテッド | ドライパウダー吸入器 |
| MX2017009112A (es) | 2015-01-14 | 2018-06-15 | Respira Therapeutics Inc | Metodos y dispositivos de dispersion de polvo. |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| EP3346990B1 (en) | 2015-09-09 | 2020-03-18 | Vectura Limited | Jet milling method |
| RU2713203C1 (ru) | 2016-03-08 | 2020-02-04 | Мерео Байофарма 1 Лимитед | Режим дозирования при лечении острых обострений хронической обструктивной болезни легких |
| JP6741773B2 (ja) | 2016-03-08 | 2020-08-19 | メレオ バイオファーマ １ リミテッド | 炎症状態の急性増悪の治療のための投与レジメン |
| EP3448389B1 (en) | 2016-06-27 | 2021-09-29 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| IL294069B2 (en) | 2017-03-01 | 2023-11-01 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
| CA3083953A1 (en) | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| JP7280627B2 (ja) | 2017-12-11 | 2023-05-24 | メレオ バイオファーマ １ リミテッド | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 |
| ES2882978T3 (es) | 2017-12-11 | 2021-12-03 | Mereo Biopharma 1 Ltd | Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en la prevención de exacerbaciones agudas de la enfermedad de obstrucción pulmonar crónica |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| HRP20240130T1 (hr) | 2019-04-04 | 2024-04-12 | Chiesi Farmaceutici S.P.A. | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza |
| KR20220066906A (ko) | 2019-09-24 | 2022-05-24 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제를 위한 신규 담체 입자 |
| WO2021178920A1 (en) | 2020-03-05 | 2021-09-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
| KR20230057404A (ko) * | 2020-08-26 | 2023-04-28 | 실라 세라퓨틱 인크. | 흡입 가능한 치료제 |
| CN112451509B (zh) * | 2020-12-19 | 2023-03-07 | 沈阳药科大学 | 一种川丁特罗吸入粉雾剂及其制备方法 |
| WO2022240897A1 (en) | 2021-05-10 | 2022-11-17 | Sepelo Therapeutics, Llc | Pharmaceutical composition comprising delafloxacin for administration into the lung |
| WO2023028364A1 (en) | 2021-08-27 | 2023-03-02 | Sepelo Therapeutics, Llc | Targeted compositions and uses therof |
| WO2023196663A1 (en) * | 2022-04-07 | 2023-10-12 | Board Of Regents, The University Of Texas System | Methods of preparing carrier-based dry powders for inhalation |
| US12029709B2 (en) * | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
| US20240261224A1 (en) | 2022-12-02 | 2024-08-08 | Kinaset Therapeutics, Inc. | Formulation of a pan-jak inhibitor |
| CN115855911B (zh) * | 2023-02-24 | 2023-06-13 | 湖南三友环保科技有限公司 | 粉末载体生物亲和性的测定方法及应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2533065A (en) * | 1947-03-08 | 1950-12-05 | George V Taplin | Micropulverized therapeutic agents |
| GB786499A (en) * | 1953-11-02 | 1957-11-20 | Grace W R & Co | A process of deagglomerating dried agglomerated microspheroidal gel catalyst particles |
| GB905723A (en) * | 1959-12-10 | 1962-09-12 | Alfred Ernest Tragham | Pharmaceutical compositions comprising phenacitin |
| GB1132583A (en) * | 1964-12-16 | 1968-11-06 | Glaxo Lab Ltd | Pharmaceutical compositions containing cephalosporins |
| GB1242212A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Drug for use in pharmaceutical composition |
| US3957965A (en) * | 1967-08-08 | 1976-05-18 | Fisons Limited | Sodium chromoglycate inhalation medicament |
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| GB1230087A (es) * | 1967-08-17 | 1971-04-28 | ||
| GB1310527A (en) * | 1969-06-13 | 1973-03-21 | Fisons Ltd | Comminuting apparatus |
| GB1381872A (en) * | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
| GB1410588A (en) * | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
| IT1197640B (it) * | 1983-05-03 | 1988-12-06 | Italsil Spa | Apparecchio e metodo per la purificazione di sabbie silicee mediante attrizione |
| EP0187433B1 (en) * | 1983-08-01 | 1990-12-27 | Teijin Limited | Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity |
| IT1204826B (it) * | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| WO1991014422A1 (en) * | 1990-03-23 | 1991-10-03 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| GB9024366D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| WO1993025193A1 (en) * | 1992-06-12 | 1993-12-23 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
| ES2177544T3 (es) * | 1992-06-12 | 2002-12-16 | Teijin Ltd | Polvo ultrafinno para inhalar y metodo para su preparacion. |
| GB2269992A (en) * | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
| ZA94155B (en) | 1992-11-06 | 1995-07-11 | Adcock Ingram Pharma | Pharmaceutical composition |
| SE9203743D0 (sv) * | 1992-12-11 | 1992-12-11 | Astra Ab | Efficient use |
| IS1796B (is) * | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| ATE363892T1 (de) * | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| EP1913939B1 (en) * | 2000-06-27 | 2017-05-31 | Vectura Limited | Formulations for use in inhaler devices |
| JP3486405B2 (ja) | 2001-08-10 | 2004-01-13 | 三菱重工業株式会社 | 減揺装置 |
-
1995
- 1995-01-31 GB GBGB9501841.2A patent/GB9501841D0/en active Pending
- 1995-10-26 GB GBGB9521937.4A patent/GB9521937D0/en active Pending
-
1996
- 1996-01-31 PT PT96901439T patent/PT806938E/pt unknown
- 1996-01-31 DK DK06004066.4T patent/DK1666023T3/da active
- 1996-01-31 BR BRPI9612950A patent/BRPI9612950B8/pt unknown
- 1996-01-31 EP EP10075119A patent/EP2213279A3/en not_active Withdrawn
- 1996-01-31 AT AT96901439T patent/ATE256450T1/de active
- 1996-01-31 US US08/875,391 patent/US6153224A/en not_active Expired - Lifetime
- 1996-01-31 KR KR1019970705241A patent/KR100500694B1/ko active IP Right Grant
- 1996-01-31 CN CNB961926767A patent/CN1303974C/zh not_active Expired - Lifetime
- 1996-01-31 CZ CZ19972443A patent/CZ294259B6/cs not_active IP Right Cessation
- 1996-01-31 ES ES02007397T patent/ES2278828T3/es not_active Expired - Lifetime
- 1996-01-31 AT AT06004066T patent/ATE526946T1/de active
- 1996-01-31 BR BRPI9612950-6A patent/BR9612950B1/pt not_active IP Right Cessation
- 1996-01-31 AU AU45456/96A patent/AU699131B2/en not_active Expired
- 1996-01-31 PT PT06004066T patent/PT1666023E/pt unknown
- 1996-01-31 EE EE9700176A patent/EE9700176A/ unknown
- 1996-01-31 DE DE69631119T patent/DE69631119T2/de not_active Expired - Lifetime
- 1996-01-31 NZ NZ300654A patent/NZ300654A/ not_active IP Right Cessation
- 1996-01-31 GE GEAP19963854A patent/GEP19991687B/en unknown
- 1996-01-31 CA CA002211874A patent/CA2211874C/en not_active Expired - Lifetime
- 1996-01-31 DK DK02007397T patent/DK1232745T3/da active
- 1996-01-31 BR BRPI9607490A patent/BR9607490B8/pt not_active IP Right Cessation
- 1996-01-31 SI SI9630777T patent/SI1666023T1/sl unknown
- 1996-01-31 AT AT02007397T patent/ATE355822T1/de active
- 1996-01-31 ES ES06004066T patent/ES2375007T3/es not_active Expired - Lifetime
- 1996-01-31 ZA ZA96721A patent/ZA96721B/xx unknown
- 1996-01-31 UA UA97084422A patent/UA61051C2/uk unknown
- 1996-01-31 DE DE69636961T patent/DE69636961T2/de not_active Expired - Lifetime
- 1996-01-31 EP EP02007397A patent/EP1232745B1/en not_active Revoked
- 1996-01-31 SI SI9630752T patent/SI1232745T1/sl unknown
- 1996-01-31 EP EP96901439A patent/EP0806938B1/en not_active Expired - Lifetime
- 1996-01-31 DK DK96901439T patent/DK0806938T3/da active
- 1996-01-31 HU HU9802209A patent/HU229965B1/hu unknown
- 1996-01-31 JP JP52335096A patent/JP4042867B2/ja not_active Expired - Lifetime
- 1996-01-31 EP EP06004066A patent/EP1666023B1/en not_active Expired - Lifetime
- 1996-01-31 EP EP01120610A patent/EP1159955A1/en not_active Withdrawn
- 1996-01-31 PT PT02007397T patent/PT1232745E/pt unknown
- 1996-01-31 WO PCT/GB1996/000215 patent/WO1996023485A1/en active IP Right Grant
- 1996-01-31 ES ES96901439T patent/ES2213172T3/es not_active Expired - Lifetime
- 1996-01-31 PL PL96321572A patent/PL186757B1/pl unknown
- 1996-01-31 EA EA199700153A patent/EA000352B1/ru not_active IP Right Cessation
- 1996-01-31 SK SK1036-97A patent/SK282630B6/sk unknown
- 1996-01-31 TR TR97/00722T patent/TR199700722T1/xx unknown
- 1996-01-31 EP EP10075470.4A patent/EP2258342A3/en not_active Withdrawn
-
1997
- 1997-07-25 IS IS4531A patent/IS4531A/is unknown
- 1997-07-30 FI FI973151A patent/FI119676B/fi not_active IP Right Cessation
- 1997-07-30 NO NO19973502A patent/NO324037B1/no not_active IP Right Cessation
- 1997-07-31 MX MX9705847A patent/MX9705847A/es unknown
- 1997-08-27 BG BG101858A patent/BG101858A/ unknown
-
2000
- 2000-10-06 US US09/680,863 patent/US6521260B1/en not_active Expired - Lifetime
-
2002
- 2002-11-27 US US10/306,865 patent/US7011818B2/en not_active Expired - Fee Related
-
2005
- 2005-08-11 US US11/202,741 patent/US7718163B2/en not_active Expired - Fee Related
-
2006
- 2006-07-03 HK HK06107484.2A patent/HK1084897A1/xx not_active IP Right Cessation
-
2010
- 2010-03-26 US US12/748,275 patent/US8920781B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324037B1 (no) | Pulver for anvendelse i en torrpulverinhalator og fremgangsmate for fremstilling av pulveret | |
| CA2353448C (en) | Improvements in or relating to powders | |
| US20150202156A1 (en) | Dry powder pharmaceutical composition, its preparation process and stable aqueous suspension obtained from such composition | |
| AU2003226842B2 (en) | A method for treating carrier particles and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |